This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Campus
  1. Article
  2. Source: Campus Sanofi
  3. 9 Apr 2024
12 min

A Real World Case Study: Presented by Christine Skeet

Author: Christine Skeet

Haematology CNS, University Hospitals of Derby and Burton

  

This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.

Prescribing Information for SARCLISA®▼ (isatuximab) can be found via the Product Card at the bottom of the page.

In this video, you'll learn about

A case study presented by Christine Skeet of an 84 year old RRMM patient who receives SARCLISA® + Pd at 4th Line. The case study examines the practical considerations of managing an elderly patient with lytic bone disease and renal impairment.

Learn more about SARCLISA®

Overview of SARCLISA®

Find out more about SARCLISA® + Pd efficacy and safety data and dosing information.

Dosing and Administration Guide

Download a handy guide to SARCLISA dosing and administration information

Patient Booklet

Download SARCLISA® patient information.

1/3

Overview of SARCLISA®

Find out more about SARCLISA® + Pd efficacy and safety data and dosing information.

Dosing and Administration Guide

Download a handy guide to SARCLISA dosing and administration information

Patient Booklet

Download SARCLISA® patient information.


 

Get in touch with
the Oncology Team

Relapsed Refractory
Multiple Myeloma Product

Sarclisa logo GB only

Learn more  →

Prescribing information GB

MAT-XU-2202578 (v4.0)
Date of preparation: June 2024

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

MAT-XU-2401194 (v1.0) Date of Preparation: June 2024